Insider · CIK 0001553489

Reasons Bryan M.

Reports to the SEC for 5 companies · HAYWARD, CA

sec.gov

Transactions

Companies

Filings

CIK

0001553489

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-07-31	Keenova Therapeutics plcRestricted Stock UnitsA Award	EVP & CFO	AAward	+41K sh	—	—	54,714
2025-01-01	Keenova Therapeutics plcM Exercise/Conversion	EVP & CFO	MExercise/Conversion	+6,838 sh	—	—	6,838
2025-01-01	Keenova Therapeutics plcF Tax Payment	EVP & CFO	FTax Payment	−1,724 sh	—	—	5,114
2025-01-01	Keenova Therapeutics plcRestricted Stock UnitsM Exercise/Conversion	EVP & CFO	MExercise/Conversion	−6,838 sh	—	—	13,679
2024-06-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,660 sh	—	—	28,732
2024-06-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−4,660 sh	—	—	0
2024-04-08	Societal CDMO, Inc.U Disposition from Tender	Director	UDisposition from Tender	−217K sh	$1.10	−$239K	73,620
2024-04-08	Societal CDMO, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−73.6K sh	$1.10	−$81K	0
2024-04-08	Societal CDMO, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−118K sh	—	—	0
2024-04-08	Societal CDMO, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−27.2K sh	—	—	0
2024-02-02	Keenova Therapeutics plcRestricted Stock UnitsA Award	EVP & CFO	AAward	−20.5K sh	—	—	20,517
2023-11-14	Keenova Therapeutics plcD Disposition to Issuer	EVP & CFO	DDisposition to Issuer	−96.7K sh	—	—	0
2023-08-28	Societal CDMO, Inc.P Purchase	Director	PPurchase	+62.5K sh	$0.40	+$25K	291,049
2023-08-17	Keenova Therapeutics plcF Tax Payment	EVP & CFO	FTax Payment	−16K sh	$0.69	−$11.1K	96,660
2023-06-30	Keenova Therapeutics plcRestricted Stock UnitsD Disposition to Issuer	EVP & CFO	DDisposition to Issuer	−168K sh	—	—	0
2023-06-02	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,507 sh	—	—	24,072
2023-06-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−4,507 sh	—	—	0
2023-06-01	ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15.8K sh	—	—	15,750
2023-06-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+4,660 sh	—	—	4,660
2023-05-17	Societal CDMO, Inc.A Award	Director	AAward	+73.6K sh	—	—	228,549
2023-05-17	Societal CDMO, Inc.Stock Option (right to buy)A Award	Director	AAward	+27.2K sh	—	—	27,229
2023-04-03	Keenova Therapeutics plcRestricted Stock UnitsA Award	EVP & CFO	AAward	+168K sh	—	—	168,237
2022-12-14	Keenova Therapeutics plcA Award	EVP & CFO	AAward	+113K sh	—	—	112,636
2022-06-16	Keenova Therapeutics plcD Disposition to Issuer	EVP & CFO	DDisposition to Issuer	−11.6K sh	—	—	0
2022-06-16	Keenova Therapeutics plcEmployee Share Options (Right to Buy)D Disposition to Issuer	EVP & CFO	DDisposition to Issuer	−57.6K sh	—	—	0
2022-06-03	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,356 sh	—	—	19,565
2022-06-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,356 sh	—	—	0
2022-06-02	ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15.8K sh	—	—	15,750
2022-06-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+4,507 sh	—	—	4,507
2022-05-18	Societal CDMO, Inc.A Award	Director	AAward	+87.5K sh	—	—	154,929
2022-05-18	Societal CDMO, Inc.Stock Option (right to buy)A Award	Director	AAward	+118K sh	—	—	118,182
2021-06-03	ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.3K sh	—	—	12,250
2021-06-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+3,356 sh	—	—	3,356
2021-04-20	Societal CDMO, Inc.Stock Option (right to buy)A Award	Director	AAward	+38K sh	—	—	38,012
2021-04-20	Societal CDMO, Inc.A Award	Director	AAward	+26.9K sh	—	—	67,429
2021-04-20	Societal CDMO, Inc.Stock Option (right to buy)A Award	Director	AAward	+38K sh	—	—	38,012
2020-12-03	Keenova Therapeutics plcS Sale	EVP & CFO	SSale	−5,400 sh	$0.17	−$891	11,593
2020-06-06	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+7,333 sh	—	—	16,209
2020-06-06	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−7,333 sh	—	—	0
2020-06-04	ACRSAclaris Therapeutics, Inc. · Option Grant (right to buy)A Award	Director	AAward	+16.5K sh	—	—	16,500
2020-05-07	Societal CDMO, Inc.A Award	Director	AAward	+8,363 sh	—	—	40,506
2020-05-07	Societal CDMO, Inc.Stock Option (right to buy)A Award	Director	AAward	+12.4K sh	—	—	12,405
2020-04-01	Keenova Therapeutics plcF Tax Payment	EVP & CFO	FTax Payment	−986 sh	$1.93	−$1,902.98	16,993
2020-03-02	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+8,876 sh	—	—	8,876
2020-03-02	ACRSAclaris Therapeutics, Inc. · Restricted stock unitsA Award	Director	AAward	+8,876 sh	—	—	8,876
2020-03-02	ACRSAclaris Therapeutics, Inc. · Restricted stock unitsM Exercise/Conversion	Director	MExercise/Conversion	−8,876 sh	—	—	0
2019-12-05	Societal CDMO, Inc.A Award	Director	AAward	+9,156 sh	—	—	32,143
2019-06-07	Keenova Therapeutics plcP Purchase	EVP & CFO	PPurchase	+5,400 sh	$8.96	+$48.4K	17,979
2019-06-06	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+7,333 sh	—	—	7,333
2019-05-09	Societal CDMO, Inc.A Award	Director	AAward	+7,955 sh	—	—	22,987

Recent filings

Accepted (ET)
Aug 44
Reasons Bryan M.0001104659-25-073784
SEC(opens sec.gov)
Jan 24
Reasons Bryan M.0001104659-25-000368
SEC(opens sec.gov)
Jun 44
Reasons Bryan M.0001415889-24-015369
SEC(opens sec.gov)
Apr 84
Reasons Bryan M.0001104659-24-044896
SEC(opens sec.gov)
Feb 64
Reasons Bryan M.0001104659-24-011128
SEC(opens sec.gov)
Nov 164
Reasons Bryan M.0001104659-23-119124
SEC(opens sec.gov)
Aug 284
Reasons Bryan M.0001062993-23-017166
SEC(opens sec.gov)
Aug 184
Reasons Bryan M.0001104659-23-093621
SEC(opens sec.gov)
Jul 54
Reasons Bryan M.0001104659-23-078291
SEC(opens sec.gov)
Jun 54
Reasons Bryan M.0001209191-23-034421
SEC(opens sec.gov)
May 194
Reasons Bryan M.0001062993-23-011843
SEC(opens sec.gov)

Companies

Address

C/O IMPAX LABORATORIES, INC. 30831 HUNTWOOD AVENUE

HAYWARD, CA, 94544